Amer Zeidan: Analyzing determinants of premature trial discontinuation in leukemia clinical trials
Amer Zeidan, Associate Professor of Medicine (Hematology) at Yale University, shared a post on X:
“Our newest paper co-led by our outstanding Yale School of Medicine resident Lara K Rotter & recent graduate Abdulrahman Alhajahjeh (applying for Match 2025 so program directors plz pay notice). Analyzing determinants of premature trial discontinuation in leukemia clinical trials.”
Analyzing determinants of premature trial discontinuation in leukemia clinical trials
Authors: Lara K. Rotter, et al.
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023